



## Bionpharma – Recall of clobazam oral suspension

- On July 31, 2019, the [FDA enforcement report announced](#) a class II, patient-level recall of one lot of Bionpharma's [clobazam](#) oral suspension due to microbial contamination.

Product Description	NDC#	Lot# (Expiration Date)
Clobazam oral suspension, 2.5 mg/mL, 120 mL bottle	69452-116-45	18246 (9/2020)

- Clobazam oral suspension is indicated for the adjunctive treatment of seizures associated with Lennox-Gastaut syndrome in patients 2 years of age or older.
- Patients should contact their healthcare provider if they have experienced any problems that may be related to using the recalled clobazam oral suspension.
- Anyone with an existing inventory of the recalled product should stop use and distribution, and quarantine the product immediately.
- For more information regarding this recall, contact Bionpharma at **1-888-235-2466**.



OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at [optum.com](#).

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2019 Optum, Inc. All rights reserved.